{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134207","form_type":"8-K","ticker":null,"cik":"0001876588","company_name":"ZimVie Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.051027+00:00","generated_at":"2026-06-02T13:40:26.208225+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ZimVie Q1 net sales $118.2M, net loss ($11.5M); completed spine sale for $375M, repaid $275M debt","bullets":["Q1 net sales from continuing ops $118.2M, down 1.6% YoY; net loss ($11.5M) improved from ($16.4M) YoY.","Adjusted EBITDA $12.5M (10.5% margin) vs $10.7M (8.8% margin) in Q1 2023; adjusted EPS $0.08.","On April 1, 2024, closed sale of spine business for $375M and repaid $275M of debt.","FY 2024 guidance: net sales $450M-$460M, adjusted EBITDA $60M-$65M, adjusted EPS $0.55-$0.70.","Company refocused as pure-play dental; weighted average shares 27.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134207","json":"https://secwatch.observer/filing/0001193125-24-134207.json","markdown":"https://secwatch.observer/filing/0001193125-24-134207.md","text":"https://secwatch.observer/filing/0001193125-24-134207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1876588/000119312524134207/0001193125-24-134207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1876588/000119312524134207/d825203d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:40:26.208225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30a48d993fba76303680b4343e99a6e6850a8726","claim":"ZimVie Inc. reported the quarter ended March 31, 2024 results: revenue $118.2 million, net income ($11.5) million, EPS ($0.42). Guidance reaffirmed.","evidence_excerpt":"part of this report. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 ZimVie Reports First Quarter 2024 Financial Results • Third Party Net Sales from Continuing Operations of $118.2 million • Net Loss from Continuing Operations of ($11.5) million; Net Loss margin of (9.7%) • Adjusted EBITDA [1] from Continuing Operations of $12.5 million; Adjusted EBITDA [1] margin","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1876588/000119312524134207/0001193125-24-134207-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$118.2 million"},{"label":"Net income","value":"($11.5) million"},{"label":"EPS","value":"($0.42)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}